Ana sa ran kasuwar magungunan rigakafin ƙwayar cuta ta duniya za ta kai dala biliyan 50.02 a cikin 2030 kuma ta yi rijistar kudaden shiga CAGR na 3.4% a lokacin annabta, bisa ga sabon rahoton da Rahotanni da Bayanai suka nuna. Haɓaka sabbin, ingantattun, da sabbin hanyoyin samar da magunguna shine babban abin da ake tsammanin zai haifar da haɓakar kudaden shiga na kasuwa yayin lokacin hasashen. Haɓakawa a cikin shari'o'in COVID-19, da kuma ci gaba da samun ingantaccen bututun samfur na magungunan rigakafi, ana tsammanin zai tallafawa kudaden shiga na haɓaka kasuwa yayin lokacin hasashen. Hanyoyi na yanzu don haɓaka hanyoyin kwantar da ƙwayoyin cuta, irin su magungunan da aka sake dawo da su, sun sami kulawa, yayin da suke bincika sabbin hanyoyin sake dawo da samfuran da aka amince da su ta kasuwanci ko ƙi da magungunan da aka rigaya don magance cututtukan numfashi na hoto. Nasarar hanyoyin warkewa na kamuwa da cuta, kamar COVID-19, Virus na rigakafi na ɗan adam (HIV), da coronavirus na ɗan adam (HCoV), a halin yanzu sun ƙunshi haɗaɗɗun magunguna biyu ko fiye, saboda suna iya jinkirta haɓaka juriya na ƙwayoyi. Wadannan hanyoyin za su iya taimakawa wajen magance barkewar cutar a cikin mawuyacin yanayi, cikin lokaci da tsada.

Haɓaka bambancin ƙwayoyin cuta na iya hana haɓakar kudaden shiga na kasuwa yayin lokacin hasashen. Kwayoyin cuta suna canzawa a cikin sauri cikin lokaci, suna sa magungunan rigakafin rigakafi na gargajiya ba su da tasiri, idan ba su da tasiri. Don haka, dole ne a samar da magungunan kashe kwayoyin cuta da ke aiki da ƙwayoyin cuta iri-iri na nunfashi don hana kamuwa da cututtukan numfashi a nan gaba. Manyan kamfanonin harhada magunguna suna tahowa da sabbin 'yan takarar maganin rigakafin kamuwa da cuta don biyan bukatu mai girma, wanda ke tallafawa karuwar kudaden shiga na kasuwa. Pfizer PFE da Merck MRK, waɗanda ke kasuwa Paxlovid da molnupiravir, bi da bi, suna mamaye kasuwar maganin rigakafin cutar ta COVID-19 a cikin Amurka Hukumar Abinci da Magunguna (FDA) ta amince da Paxlovid da molnupiravir a matsayin sabon zaɓin maganin rigakafin ƙwayar cuta na baka don marasa asibiti COVID- 19 kamuwa da cuta kuma ya ba su izini don amfani da gaggawa a cikin Disamba 2021.

ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:

Increase in COVID-19 cases, as well as continuous availability of a robust product pipeline of antiviral drugs, are expected to support market growth revenue during the forecast period.
The Food and Drug Administration (FDA) approved Paxlovid and molnupiravir as new oral antiviral drug options for non-hospitalized COVID-19 infections and authorized them for emergency use in December 2021.
Pfizer PFE and Merck MRK, which market Paxlovid and molnupiravir, respectively, are dominating the COVID-19 antiviral treatment market in the U.